Pion therapy at TRIUMF. Treatment results for astrocytoma grades 3 and 4: a pilot study.
At TRIUMF, (located on the University of B.C. Campus), 53 patients with supratentorial astrocytoma grades 3 and 4 were treated with pions between 1982 and 1985. A 3-dimensional spot-scanning treatment technique has proven to be practical. The accuracy of the beam alignment system used for treatment was reproducible daily within 2 mm. Low pion flux has hindered optimal beam shaping but this will soon be remedied as flux improves. The overall median survival observed (53 patients) is 262 days from date of first radiation treatment. Younger (less than 49 years) patients have significantly better survival than older (greater than 50 years) patients (p = 0.001). From a base line dose of 40 Gy photons whole brain and 17.5 Gy pion boost, doses were escalated to 33 Gy pions localised to the primary tumour and the median survival improved from 198 to 436 days. Survival curves for patients treated with localised pion techniques to doses above 30 Gy are significantly better than for those treated with schedules of pions mixed with photons (p = 0.04). It appears that optimal pion dose for brain tumours is 33 Gy minimum with a possible maximum of 36 Gy and doses delivered in 15 fractions in 3 weeks. Requirements for future trials are discussed.
Goodman
G B
GB
Department of Developmental Radiotherapy, CCABC, Vancouver, Canada.
Skarsgard
L D
LD
Thompson
G B
GB
Harrison
R
R
Lam
G K
GK
Lugate
C
C
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000401:mortality / Q000532:radiotherapy* / Q000628:therapy; D001955:British Columbia / Q000453:epidemiology; D003131:Combined Modality Therapy; D004601:Elementary Particles; D005260:Female; D005909:Glioblastoma / Q000401:mortality / Q000532:radiotherapy* / Q000628:therapy; D006801:Humans; D008297:Male; D008651:Mesons; D008875:Middle Aged; D010315:Particle Accelerators; D010865:Pilot Projects; D011829:Radiation Dosage; D011882:Radiotherapy, High-Energy / Q000009:adverse effects / Q000379:methods*; D015996:Survival Rate
D000970:Antineoplastic Agents